BioLineRx (BLRX) Liabilities and Shareholders Equity (2010 - 2026)

BioLineRx's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $40.9 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 5.14% year-over-year to $40.9 million; the TTM figure through Dec 2025 stood at $167.5 million (down 19.42% YoY), while the FY2025 annual figure was $40.9 million, up 5.14% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $40.9 million, up from $39.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $91.3 million in Q2 2021, with the low at $38.9 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $64.3 million (2023), against an average of $63.2 million.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity surged 88.76% in 2021, then tumbled 39.14% in 2024.
• BioLineRx's Liabilities and Shareholders Equity stood at $81.4 million in 2021, then slipped by 6.15% to $76.4 million in 2022, then slipped by 16.31% to $63.9 million in 2023, then slumped by 39.14% to $38.9 million in 2024, then grew by 5.14% to $40.9 million in 2025.
• Business Quant data shows BLRX's Liabilities and Shareholders Equity at $40.9 million in Q4 2025, $39.8 million in Q3 2025, and $43.3 million in Q2 2025.